BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of ...
A recent study supported by the National Institutes of Health (NIH) and published in Nature Neuroscience found that Alzheimer ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
People sense millisecond shifts in odor as quickly as they might spot a change in color, new research shows. The study ...
Enrollment in a 2025 Medicare plan opened for beneficiaries today. News outlets focus on an array of changes that could lead to "benefit disruption" that consumers should know about, in particular ...
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...